Members Wealth LLC Purchases Shares of 101,382 DiaMedica Therapeutics, Inc. $DMAC

Members Wealth LLC purchased a new stake in shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 101,382 shares of the company’s stock, valued at approximately $864,000.

Other hedge funds have also added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new stake in DiaMedica Therapeutics during the 3rd quarter valued at $27,000. Bank of America Corp DE lifted its holdings in DiaMedica Therapeutics by 3,710.3% during the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock valued at $33,000 after purchasing an additional 8,274 shares during the last quarter. Farther Finance Advisors LLC acquired a new stake in DiaMedica Therapeutics during the 4th quarter valued at $34,000. JPMorgan Chase & Co. acquired a new stake in DiaMedica Therapeutics during the 2nd quarter valued at $49,000. Finally, Invesco Ltd. acquired a new stake in DiaMedica Therapeutics during the 2nd quarter valued at $54,000. Institutional investors and hedge funds own 10.12% of the company’s stock.

DiaMedica Therapeutics Stock Performance

DMAC opened at $6.22 on Friday. DiaMedica Therapeutics, Inc. has a fifty-two week low of $3.47 and a fifty-two week high of $10.42. The company has a market capitalization of $335.13 million, a P/E ratio of -8.89 and a beta of 1.16. The stock has a fifty day moving average of $7.24 and a 200-day moving average of $7.59.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its earnings results on Monday, March 30th. The company reported ($0.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.17). The firm had revenue of ($0.03) million for the quarter, compared to analyst estimates of $13.50 million. On average, equities research analysts predict that DiaMedica Therapeutics, Inc. will post -0.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Monday. Lake Street Capital reaffirmed a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $12.33.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.